NSE: INFY · BSE: 500209 · ISIN INE009A01021
Infosys Limited stock analysis
Infosys Limited ranks #657 in the TickerSutra evidence-ranked universe with a score of 62/100 and 95% data confidence. The latest captured fundamentals show ROCE of 40.0%, quarterly sales growth of 14.0% and quarterly profit growth of 12.3%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- ROCE is 40%
- Low debt/equity of 0.1×
- Strong CFO/EBITDA of 0.8×
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- Promoter holding is below 25%
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹1,21,641cr | ₹31,491cr | ₹22,146cr | 26.0% |
| 2023 | ₹1,46,767cr | ₹35,130cr | ₹24,108cr | 24.0% |
| 2024 | ₹1,53,670cr | ₹36,425cr | ₹26,248cr | 24.0% |
| 2025 | ₹1,62,990cr | ₹39,236cr | ₹26,750cr | 24.0% |
| 2026 | ₹1,78,650cr | ₹42,280cr | ₹29,474cr | 24.0% |
| TTM | ₹1,84,582cr | ₹43,745cr | ₹30,325cr | 24.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Allotment of equity shares towards exercise of ESOPs
RoutineInfosys Ltd - 500209 - Infosys Foundation Collaborates With Madras Medical College To Strengthen Cardio-Obstetric Care For Pregnant WomenBSE · 9 Sept 2026Enclosed
RoutineUpdatesNSE · 9 Sept 2026Infosys Limited has informed the Exchange regarding 'Infosys Foundation Collaborates with Madras Medical College to Strengthen Cardio-Obstetric Care for Pregnant Women'.
MANAGEMENT COMMENTARY
Signals from filed documents
Macroeconomic uncertainty continues to infl uence client spending patterns and decision-making timelines. Clients are driving business priorities, including cost optimization, operational resilience, productivity improvements and regulatory compliance. Generative AI is emerging as a strong growth catalyst, driving process re-im agination and productivity initiative s.
Jayesh Sanghrajka Jonathan, we are not saying that we are not seei ng a price increase. What I am saying here is, we have not seen as much price increase that we envisaged at the beginning of the year on the back of the AI productivity ask of the clients, plus the intensifying competitiveness in the market. But we are still seeing a net increase in the pricing.
(3) a) Remuneration includes ₹50.75 crore pertaining to exercise of 2,72,400 Restricted Stock Units (RSUs) under the 2015 Plan and 64,690 RSUs under the 2019 Plan during fiscal 2026. b) On the recommendation of the Nomination and Remuneration Committee and as approved by the shareholders, in accordance with the terms of his employment agreement effective July 1, 2022, the Board approved i) the grant of 2,30,621 perfo
And then on the earnings, of course, the reason for this revision downwards, if you could give us a little more colou r on what you are seeing in the environment, where is the weakness? Some of your competitors like Tech M have been talking about irrational competitive pricing. Wipro has also spoken about that a bit.
As we look at the rest of the year, we remain co nfident in our strategy, discipline in our investments and focus on delivering stronger performance. Margin guidance is maintained at 20% to 22%. This assumes headwind from wage hikes productivity pa ss-throughs, AI investments and 50 basis point impact from acquisitions of Optimum Healthcare and Stratus.
Engineering Accelerates the full spectrum of software delivery by combining modern architectures, intelligent automation, and AI-driven execution. It spans greenfield engineering, application modernization, platform and cloud migration, data and quality engineering, and process re-engineering. By embedding intelligence across build, migrate, and run phases, engineering enables scalable, resilient, and future-ready di
Results of our operations For details about results of our operations, refer to 'Results of our operations and state of affairs' section in the Boards' report . During fiscal 2026, the Company continued running Project Maximus, a comprehensive margin expansion program structured across five pillars – Value-based selling; Efficient pyramid; Lean, automation and gen AI; Improving key portfolios, and Optimization of ind
Trading opened at ₹145 per share, compared to the IPO price of ₹95 per share. In October 1994, we made a private placement of 5,50,000 shares at ₹450 each to Foreign Institutional Investors (FIIs), Financial Institutions (FIs), and body corporates. On March 11, 1999, Infosys listed on NASDAQ, becoming the first Indian company to do so.
MANAGEMENT PROMISE LEDGER
Quantified statements on the clock
“As we look at the rest of the year, we remain co nfident in our strategy, discipline in our investments and focus on delivering stronger performance. Margin guidance is maintained at 20% to 22%. This assumes headwind from wage hikes productivity pa ss-throughs, AI investments and 50 basis point impact from acquisitions of Optimum Healthcare and Stratus.”
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…